|GEMS has released its Annual Report for 2017. The annual report shares the data and insights from the program’s second year of operations and looks ahead to new innovations in 2018 building off these lessons learned. GEMS has also released its Surveillance Bulletin for Q1 2018, detailing the testing and positivity rates of our four GEMS country operations in the first quarter of 2018.
Please click below to read the full reports!
|Countries in the GMS have successfully brought down the number of malaria cases in the region over recent years and elimination is now in sight. This goal is urgent: the drugs and insecticides we use to fight malaria are losing their effectiveness and the GMS has historically been the epicenter for drug resistance. Malaria needs to be eliminated before it is too late for Asia, and before resistance spreads to Africa where malaria continues to take hundreds of thousands of lives every year.
GEMS takes a unique approach to malaria elimination:
|PSI is investing in the development and the roll out of intuitive, innovative tech solutions.
Click the content below to learn more.
|Why the private sector?
In Southeast Asia, between 40-70% of the population first seek health care in the private sector, meaning that private providers potentially see most of the malaria cases in the region. It is therefore critical that private sector outlets are able to test for malaria, and are stocked with the right drugs in order to provide correct treatment.
Which providers does GEMS work with?